Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMC-001 in Acute Coronary Syndrome
NCT06788431Phase 1Recruiting
- Sponsor
- ImmuneOnco
- Start
- Mar 2025
- Primary completion
- Oct 2026
- Modality
- CAR-T Cells, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in acute coronary syndrome (ACS) comparing IMC-001 and Optimal medical treatment with IMC-001 placebo and optimal medical treatment (2 arms). Primary endpoint: Low-Attenuation Plaque Volume at 6 months. Started Mar 2025; status: recruiting.
02
Drugs
IMC-001
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on NCT06788431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06788431.